product summary
Loading...
company name :
R&D Systems
product type :
ELISA/assay
product name :
PD-L1/B7-H1 ELISA
catalog :
DB7H10
quantity :
1 Kit
price :
680 USD
more info or order :
citations: 23
Reference
Lafoux B, Fourcaud G, Hortion J, Soyer L, Journeaux A, Germain C, et al. Expansion of myeloid suppressor cells and suppression of Lassa virus-specific T cells during fatal Lassa fever. PLoS Pathog. 2025;21:e1013111 pubmed publisher
Yuan Q, Fan Z, Huang W, Huo X, Yang X, Ran Y, et al. Human cytomegalovirus UL23 exploits PD-L1 inhibitory signaling pathway to evade T cell-mediated cytotoxicity. MBio. 2024;15:e0119124 pubmed publisher
Eslami S Z, Cort xe9 s Hern xe1 ndez L, Sinoquet L, Gauthier L, Vautrot V, Cayrefourcq L, et al. Circulating tumour cells and PD-L1-positive small extracellular vesicles: the liquid biopsy combination for prognostic information in patients with metastatic non-small cell lung cancer. Br J Cancer. 2024;130:63-72 pubmed publisher
Kir xe1 ly Z, Nagy E, Bokor L, Kov xe1 cs A, Marschalk xf3 M, Hidv xe9 gi B. The Possible Clinical Significance of a Decreased Serum Level of Soluble PD-L1 in Discoid Lupus Erythematosus, but Not in Subacute Cutaneous Lupus Erythematosus-A Pilot Study. J Clin Med. 2023;12: pubmed publisher
Zhang L, Li H, Liu J, Sun G, Tang X, Xu S, et al. The screening of compounds regulating PD-L1 transcriptional activity in a cell functional high-throughput manner. Cancer Med. 2023;12:9815-9825 pubmed publisher
Ma J, Zhou Q, Xu W, Li C, Wang H, Zhai Z, et al. Urine PD-L1 is a tumor tissue candidate substitute and is associated with poor survival in muscle-invasive bladder cancer patients. Int Immunopharmacol. 2023;114:109535 pubmed publisher
Sz xe9 les x, Kov xe1 cs P, Csizmarik A, V xe1 radi M, Riesz P, Fazekas T, et al. High Pretreatment Serum PD-L1 Levels Are Associated with Muscle Invasion and Shorter Survival in Upper Tract Urothelial Carcinoma. Biomedicines. 2022;10: pubmed publisher
Munoz O, Banga R, Schelling R, Procopio F, Mastrangelo A, Nortier P, et al. Active PD-L1 incorporation within HIV virions functionally impairs T follicular helper cells. PLoS Pathog. 2022;18:e1010673 pubmed publisher
Chávez Galán L, Ruiz A, Martinez Espinosa K, Aguilar Duran H, Torres M, Falfan Valencia R, et al. Circulating Levels of PD-L1, TIM-3 and MMP-7 Are Promising Biomarkers to Differentiate COVID-19 Patients That Require Invasive Mechanical Ventilation. Biomolecules. 2022;12: pubmed publisher
Nakano K, Yokoyama K, Shin S, Uchida K, Tsuji K, Tanaka M, et al. Exploring New Functional Aspects of HTLV-1 RNA-Binding Protein Rex: How Does Rex Control Viral Replication?. Viruses. 2022;14: pubmed publisher
Keber C, Derigs M, Schultz C, Wegner M, Lingelbach S, Wischmann V, et al. Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood. Cancer Immunol Immunother. 2022;71:2381-2389 pubmed publisher
Vikerfors A, Davidsson S, Frey J, Jerlström T, Carlsson J. Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients. Cancers (Basel). 2021;13: pubmed publisher
Mao C, Wang S, Su Y, Tseng S, He L, Wu A, et al. Protein detection in blood with single-molecule imaging. Sci Adv. 2021;7: pubmed publisher
Tosev G, Wahafu W, Reimold P, Damgov I, Schwab C, Aksoy C, et al. Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder. Sci Rep. 2021;11:14244 pubmed publisher
Mocan T, Ilies M, Nenu I, Craciun R, Horhat A, Susa R, et al. Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma. Int Immunopharmacol. 2021;94:107467 pubmed publisher
Xu J, Wang J, Wang X, Tan R, Qi X, Liu Z, et al. Soluble PD-L1 improved direct ARDS by reducing monocyte-derived macrophages. Cell Death Dis. 2020;11:934 pubmed publisher
Fei Y, Yu J, Li Y, Li L, Zhou S, Zhang T, et al. Plasma soluble PD-L1 and STAT3 predict the prognosis in diffuse large B cell lymphoma patients. J Cancer. 2020;11:7001-7008 pubmed publisher
Cui L, Chen S, Lerbs T, Lee J, Domizi P, Gordon S, et al. Activation of JUN in fibroblasts promotes pro-fibrotic programme and modulates protective immunity. Nat Commun. 2020;11:2795 pubmed publisher
Castello A, Rossi S, Toschi L, Mansi L, Lopci E. Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters. Cancers (Basel). 2020;12: pubmed publisher
Chiarucci C, Cannito S, Daffinà M, Amato G, Giacobini G, Cutaia O, et al. Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival. Cancers (Basel). 2020;12: pubmed publisher
Yang J, Hu G. Significance of PD-L1 in the diagnosis and treatment of B-cell malignant lymphoma. Oncol Lett. 2019;17:3382-3386 pubmed publisher
Jin J, Si J, Liu Y, Wang H, Ni R, Wang J. Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy. Respir Res. 2018;19:197 pubmed publisher
Kim H, Park S, Kim K, Seong J. Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy. Radiother Oncol. 2018;129:130-135 pubmed publisher
product information
brand :
R&D Systems
master code :
DB7H10
SKU :
DB7H10
product name :
PD-L1/B7-H1 ELISA
sizes available :
1 Kit
description :
The Human/Cynomolgus Monkey PD-L1/B7-H1 Quantikine ELISA Kit from DB7H10 quantifies human, cynomolgus monkey 4.5 hours in 4.52 pg/ml.
target :
PD-L1/B7-H1
category :
ELISAs
dilution :
ELISA
species :
Human, Cynomolgus Monkey
specificity :
Natural and recombinant human B7-H1/PD-L1. This assay also recognizes natural cynomolgus monkey B7-H1/PD-L1.
assay length :
4.5 hours
elisaSampleTypes :
Cell Culture Supernates (100 uL), Cell Lysates (100 uL), Serum (100 uL), EDTA Plasma (100 uL), Heparin Plasma (100 uL), Urine (100 uL)
elisaSensitivity :
4.52 pg/mL
elisaRange :
25.00 - 1600 pg/mL
top caption :
Human PD-L1/B7-H1 ELISA Cell Culture Supernate/Cell Lysate/Serum/Plasma Standard Curve
applications :
ELISA
extended description :
Quantikine Quickit version available - results in 90 minutes (QK1146).
USD :
680 USD
product details :
The Quantikine® Human/Cynomolgus Monkey B7-H1/PD-L1 Immunoassay is a 4.5 hour solid-phase ELISA designed to measure human/cynomolgus monkey B7-H1 in cell culture supernates, cell lysates, serum, plasma, and urine. It contains HEK293-expressed recombinant human B7-H1/PD-L1 and has been shown to accurately quantitate the recombinant factor. Results obtained using natural human/cynomolgus monkey B7-H1/PD-L1 showed linear curves that were parallel to the standard curves obtained using the Quantikine® kit standards. These results indicate that this kit can be used to determine relative mass values for naturally occurring human/cynomolgus monkey B7-H1/PD-L1. Read this White Paper on detecting B7-H1/PD-L1 levels in multiple cancer subtypes.
alt names :
Avelumab, B7-H, B7H1, B7-H1, B7H1PDCD1L1, CD274, CD274 antigenMGC142294, CD274 molecule, PDCD1L1, PDCD1LG1, PDCD1LG1MGC142296, PDL1, PD-L1, PD-L1B7 homolog 1, PDL1PDCD1 ligand 1, programmed cell death 1 ligand 1, Programmed death ligand 1
storage :
Store the unopened product at 2 - 8 °C. Do not use past expiration date.
more info or order :
company information
R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com
800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.